Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 7:05 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 3,978 matching trials from the live ClinicalTrials.gov search.
Conditions
Depression, Cognition Disorders
Interventions
Problem Solving Therapy, Brief Supportive Therapy
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
60 Years and older
Enrollment
221 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
2
States / cities
San Francisco, California • White Plains, New York
Conditions
Lower Extremity Dysfunction, Stroke
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 99 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Scottsdale, Arizona
Conditions
Friedreich Ataxia
Interventions
Omaveloxolone Capsules, 2.5 mg, Omaveloxolone Capsules, 5 mg, Omaveloxolone Capsules, 10 mg, Placebo, Omaveloxolone Capsules, 20 mg, Omaveloxolone Capsules, 40 mg, Omaveloxolone Capsules, 80 mg, Omaveloxolone Capsules, 160 mg, Omaveloxolone Capsules, 300 mg, Omaveloxolone Capsules, 150 mg
Drug
Lead sponsor
Biogen
Industry
Eligibility
16 Years to 40 Years
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
7
States / cities
Los Angeles, California • Gainesville, Florida • Tampa, Florida + 4 more
Conditions
Mild Cognitive Impairment
Interventions
PRISEM Remote
Behavioral
Lead sponsor
Emory University
Other
Eligibility
50 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Atlanta, Georgia
Completed No phase listed Observational Accepts healthy volunteers Results available

Early Experience With Descemet's Stripping Automated Endothelial Keratoplasty

NCT00744796
Conditions
Corneal Edema Secondary to Corneal Endothelial Dystrophy
Interventions
DSAEK, Anterior Segment Optical Coherence Topography (OCT), Best Spectacle Corrected Visual Acuity (BSCVA)
Procedure · Diagnostic Test
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
Dallas, Texas
Not listed No phase listed Observational Accepts healthy volunteers

Linus Health CDS Retrospective Validation Study

NCT05900310
Conditions
Cognitive Impairment, Motor Disorders, Dementia
Interventions
Core Cognitive Evaluation (CCE)
Diagnostic Test
Lead sponsor
Linus Health, Inc.
Industry
Eligibility
55 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Boston, Massachusetts
Completed Not applicable Interventional Accepts healthy volunteers Results available

Modulation Effects of Baduanjin Exercise on Subjective Cognitive Decline

NCT04009382
Conditions
Cognitive Decline
Interventions
Baduanjin Exercise, Cognitive Fitness Program
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
50 Years to 80 Years
Enrollment
124 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
1
States / cities
Charlestown, Massachusetts
Recruiting Not applicable Interventional

taVNS + CCT for Neurocognitive Rehab

NCT07517237
Conditions
Psychosocial Well-being, Neurocognitive Function, Cognitive Complaint, Cognitive Dysfunction
Interventions
taVNS, Computerized Cognitive Training
Device
Lead sponsor
Medical University of South Carolina
Other
Eligibility
45 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Charleston, South Carolina
Conditions
Spinal Cord Injuries, Cognitive Dysfunction, Cognitive Impairment, Acute Spinal Cord Injury
Interventions
game-like computerized activities, Placebo
Behavioral
Lead sponsor
Kessler Foundation
Other
Eligibility
18 Years to 59 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
3
States / cities
Englewood, Colorado • East Hanover, New Jersey • Seattle, Washington
Completed No phase listed Observational Accepts healthy volunteers

Implications for Management of PET Amyloid Classification Technology

NCT02778971
Conditions
Mild Cognitive Impairment, Dementia, Alzheimer's Disease
Interventions
[18F]Flutemetamol
Drug
Lead sponsor
University of Utah
Other
Eligibility
45 Years to 90 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Schizophrenia, Schizoaffective Disorder, Cognitive Impairment
Interventions
Guanfacine/Tenex
Drug
Lead sponsor
Research Foundation for Mental Hygiene, Inc.
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2008
U.S. locations
3
States / cities
New York, New York • The Bronx, New York • W. Brentwood, New York
Conditions
Mild Cognitive Impairment
Interventions
Motivationally-Enhanced Compensatory Cognitive Training (ME-CCT) Booster Modules, Treatment As Usual
Behavioral · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
55 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
San Diego, California
Conditions
Diabetes Mellitus, Type 2, Hyperuricemia
Interventions
Low-fructose diet, isocaloric, Allopurinol, Placebo, Low-fructose, hypocaloric
Other · Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
40 Years to 75 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Columbia, Missouri
Conditions
Dementia, Mild Cognitive Impairment
Interventions
Templated, clinician-facilitated intervention to align everyday living preferences assessment
Behavioral
Lead sponsor
Mclean Hospital
Other
Eligibility
55 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Belmont, Massachusetts
Conditions
Cognitive Disorders
Interventions
SUVN-D4010, Placebo
Drug
Lead sponsor
Suven Life Sciences Limited
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Lenexa, Kansas
Completed Not applicable Interventional Accepts healthy volunteers Results available

ENgaging in Advance Care Planning Talks Group Visit Intervention for Cognitive Impairment

NCT03711396
Conditions
Mild Cognitive Impairment
Interventions
Advance Care Planning Group Visits
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
65 Years and older
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
2
States / cities
Aurora, Colorado
Conditions
Gastroesophageal Reflux
Interventions
externally applied cricoid cartilage pressure
Device
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
20 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Conditions
Systemic Lupus Erythematosus
Interventions
Dehydroepiandrosterone (DHEA)
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older · Female only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Post-Acute COVID-19 Syndrome, Cognitive Dysfunction
Interventions
Pascal device, Sham Device
Device
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
New York, New York
Conditions
Cognitive Impairment
Interventions
Speed of Processing Training, Transfer Package from CI Therapy
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Birmingham, Alabama
Completed Not applicable Interventional Results available

Neonatal Gastro-Esophageal Reflux Disease (GERD) Management Trial

NCT02486263
Conditions
Gastroesophageal Reflux Disease
Interventions
Study Arm - acid suppression plus feeding bundle, Conventional arm - acid suppression only
Other
Lead sponsor
Sudarshan Jadcherla
Other
Eligibility
34 Weeks to 60 Weeks
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Hypertrophic Cardiomyopathy, Non-ischemic Dilated Cardiomyopathy, Microvascular Ischaemia of Myocardium
Interventions
Regadenoson, Adenosine
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Metabolic Dysfunction-Associated Steatohepatitis (MASH), Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)
Interventions
LY3849891, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
13
States / cities
Chandler, Arizona • Orange, California • Rialto, California + 8 more
Completed Phase 4 Interventional Results available

Mild Cognitive Impairment in Parkinson's Disease

NCT01519271
Conditions
Parkinson's Disease, Mild Cognitive Impairment
Interventions
Exelon Patch (rivastigmine transdermal system), Placebo Patches
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
40 Years to 85 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania